stockrow
Friday 6 November 2026
Export ARGX’s income statement to Excel — free account
argenex SE
ARGX Healthcare Biotechnology
argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024.
- Revenue
- +52.1%
- EPS
- +43.9%
- Free cash flow
- +537.5%
Quarter to September 2026, against a year earlier
917.19
22.42
+2.51%
Follow ARGX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | 5 | — | 5 |
+8 more TTM periods Free account |
| 0.00% | 27.07% | 0.00% | 22.63% | ||
| 0.00% | 23.15% | 0.00% | 19.54% | ||
ROIC |
0.00% | 20.71% | 0.00% | 17.19% | |
Return on Tangible Assets |
0.00% | 26.22% | 0.00% | 22.96% | |
Average Days of Receivables |
0.00 | 132.94 | 0.00 | 142.37 | |
Free Cash Flow per Share |
0.00 | 22.12 | 0.00 | 9.60 | |
Free Cash Flow |
— | 1,378.46 | — | 588.50 | |
Capital Expenditures |
— | (236.98) | — | (251.29) | |
| Other line items | |||||
Cash ROIC |
— | 11.49% | — | 5.44% | |
Accounts Receivable Turnover |
0.00 | 4.10 | 0.00 | 3.94 | |
Accounts Payable Turnover |
0.00 | 0.53 | 0.00 | 0.54 | |
Inventory Turnover |
0.00 | 1.50 | 0.00 | 1.15 | |
Average Days of Payables |
0.00 | 1,053.96 | 0.00 | 1,026.16 | |
Days of Inventory on Hand |
0.00 | 258.10 | 0.00 | 383.90 | |
Tax Rate |
(0.01) | (0.02) | (0.01) | 0.01 | |
Research and Development Expense of Revenue |
30.29% | 31.00% | 31.47% | 32.11% | |
Selling, General and Administrative Expense of Revenue |
30.36% | 28.86% | 30.42% | 32.18% | |
Share Based Compensation of Revenue |
0.00% | 13.35% | 0.00% | 16.40% | |
Interest Coverage |
426.21 | 392.41 | 320.63 | 258.16 | |
Operating CF/Net income |
0.00 | 0.94 | 0.00 | 0.65 | |
Depreciation/Fixed assets |
— | 1.45 | — | 1.40 | |
Capex/Depreciation |
— | (3.13) | — | (3.74) | |
Revenue per Share |
94.51 | 85.52 | 76.61 | 69.31 | |
Operating CF per Share |
0.00 | 25.92 | 0.00 | 13.70 | |
Capex per Share |
0.00 | (3.80) | 0.00 | (4.10) | |
Capex to Sales |
0.00 | 0.04 | 0.00 | 0.06 |
Columns are period end dates · fundamentals updated 2 Nov 2026